Moderna Surges to Record High as Vaccine Maker Added to S&P 500

Thestreet2021-07-16

Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week. Moderna will replaceAlexion Pharmaceuticals (ALXN) in the ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Yuantheshao
2021-07-19
Yuantheshao
went up almost double from may
BBKK
2021-07-19
BBKK
Ok! Good
N3o
2021-07-18
N3o
To the moon
kc0001
2021-07-17
kc0001
Go !
moneytome
2021-07-17
moneytome
Sounds like a good achievement
ziqii
2021-07-17
ziqii
i took moderna vaccine!
- ziqii:
  anybody else?
- ziqii:
  no one?
- ianjie:
  me too!
- ziqii:
  cool
- ziqii回复ziqii:
  cool cool

发表看法

226

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1168174427?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-16 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168174427","market":"us","top_or_hot":-1,"title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500","media":"Thestreet","content":"<div>\n<p>Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALXN","symbol_name":"亚力兄制药","start_time":0,"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","article_id":"1168174427","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","pubTimestamp":1626445586,"sourceInfo":null,"weMediaInfo":null,"summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","collect":0,"end_time":0,"defaultTopTitle":"thestreet.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALXN":"亚力兄制药","AZN":"阿斯利康","MRNA":"Moderna, Inc."},"translate_title":"随着疫苗制造商加入标普500，莫德纳飙升至创纪录高位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALXN":0.9,"AZN":0.9,"MRNA":0.9},"content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":173677582,"gmtCreate":1626660080746,"gmtModify":1631891069907,"author":{"id":"3578783818212467","authorId":"3578783818212467","authorIdStr":"3578783818212467","name":"Yuantheshao","avatar":"https://static.tigerbbs.com/665d183c360fb1726eb96d8f2625d142","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3578783818212467"},"htmlText":"went up almost double from may","listText":"went up almost double from may","text":"went up almost double from may","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173677582","repostId":1168174427,"repostType":4,"repost":{"id":"1168174427","pubTimestamp":1626445586,"share":"https://www.laohu8.com/m/news/1168174427?lang=&edition=full","pubTime":"2021-07-16 22:26","market":"us","language":"en","title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500","url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","media":"Thestreet","summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","content":"<p>Moderna Inc.&nbsp;(<b>MRNA</b>)&nbsp;shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&amp;P 500 benchmark next week.</p>\n<p>Moderna will replaceAlexion Pharmaceuticals&nbsp;(<b>ALXN</b>) &nbsp;in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca&nbsp;(<b>AZN</b>)&nbsp;in December of last year.</p>\n<p>Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p>\n<p>Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p>\n<p>Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p>\n<p>\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p>\n<p>Last month, the groupformally asked the U.S. Food &amp; Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p>\n<p>Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p>\n<p>The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","AZN":"阿斯利康","ALXN":"亚力兄制药"},"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168174427","content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173144893,"gmtCreate":1626650301612,"gmtModify":1633925351866,"author":{"id":"4089409912576010","authorId":"4089409912576010","authorIdStr":"4089409912576010","name":"BBKK","avatar":"https://static.tigerbbs.com/50e16ff101160c30777ec2fc744874fc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089409912576010"},"htmlText":"&nbsp;Ok! Good&nbsp;","listText":"&nbsp;Ok! Good&nbsp;","text":"Ok! Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173144893","repostId":1168174427,"repostType":4,"repost":{"id":"1168174427","pubTimestamp":1626445586,"share":"https://www.laohu8.com/m/news/1168174427?lang=&edition=full","pubTime":"2021-07-16 22:26","market":"us","language":"en","title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500","url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","media":"Thestreet","summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","content":"<p>Moderna Inc.&nbsp;(<b>MRNA</b>)&nbsp;shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&amp;P 500 benchmark next week.</p>\n<p>Moderna will replaceAlexion Pharmaceuticals&nbsp;(<b>ALXN</b>) &nbsp;in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca&nbsp;(<b>AZN</b>)&nbsp;in December of last year.</p>\n<p>Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p>\n<p>Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p>\n<p>Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p>\n<p>\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p>\n<p>Last month, the groupformally asked the U.S. Food &amp; Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p>\n<p>Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p>\n<p>The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","AZN":"阿斯利康","ALXN":"亚力兄制药"},"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168174427","content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173311575,"gmtCreate":1626615537997,"gmtModify":1631890019863,"author":{"id":"3559302440310095","authorId":"3559302440310095","authorIdStr":"3559302440310095","name":"N3o","avatar":"https://static.tigerbbs.com/d739e96217946a0031fbb6c817543a2d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3559302440310095"},"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173311575","repostId":1168174427,"repostType":4,"repost":{"id":"1168174427","pubTimestamp":1626445586,"share":"https://www.laohu8.com/m/news/1168174427?lang=&edition=full","pubTime":"2021-07-16 22:26","market":"us","language":"en","title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500","url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","media":"Thestreet","summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","content":"<p>Moderna Inc.&nbsp;(<b>MRNA</b>)&nbsp;shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&amp;P 500 benchmark next week.</p>\n<p>Moderna will replaceAlexion Pharmaceuticals&nbsp;(<b>ALXN</b>) &nbsp;in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca&nbsp;(<b>AZN</b>)&nbsp;in December of last year.</p>\n<p>Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p>\n<p>Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p>\n<p>Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p>\n<p>\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p>\n<p>Last month, the groupformally asked the U.S. Food &amp; Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p>\n<p>Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p>\n<p>The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","AZN":"阿斯利康","ALXN":"亚力兄制药"},"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168174427","content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179287359,"gmtCreate":1626534608271,"gmtModify":1633926006471,"author":{"id":"3575724178824304","authorId":"3575724178824304","authorIdStr":"3575724178824304","name":"kc0001","avatar":"https://static.tigerbbs.com/062c8e5b423cb71c4bb39132d10309e1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575724178824304"},"htmlText":"Go !","listText":"Go !","text":"Go !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179287359","repostId":1168174427,"repostType":4,"repost":{"id":"1168174427","pubTimestamp":1626445586,"share":"https://www.laohu8.com/m/news/1168174427?lang=&edition=full","pubTime":"2021-07-16 22:26","market":"us","language":"en","title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500","url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","media":"Thestreet","summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","content":"<p>Moderna Inc.&nbsp;(<b>MRNA</b>)&nbsp;shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&amp;P 500 benchmark next week.</p>\n<p>Moderna will replaceAlexion Pharmaceuticals&nbsp;(<b>ALXN</b>) &nbsp;in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca&nbsp;(<b>AZN</b>)&nbsp;in December of last year.</p>\n<p>Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p>\n<p>Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p>\n<p>Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p>\n<p>\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p>\n<p>Last month, the groupformally asked the U.S. Food &amp; Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p>\n<p>Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p>\n<p>The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","AZN":"阿斯利康","ALXN":"亚力兄制药"},"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168174427","content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179208348,"gmtCreate":1626527687284,"gmtModify":1631890292537,"author":{"id":"4087193663123660","authorId":"4087193663123660","authorIdStr":"4087193663123660","name":"moneytome","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087193663123660"},"htmlText":"Sounds like a good achievement","listText":"Sounds like a good achievement","text":"Sounds like a good achievement","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179208348","repostId":1168174427,"repostType":4,"repost":{"id":"1168174427","pubTimestamp":1626445586,"share":"https://www.laohu8.com/m/news/1168174427?lang=&edition=full","pubTime":"2021-07-16 22:26","market":"us","language":"en","title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500","url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","media":"Thestreet","summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","content":"<p>Moderna Inc.&nbsp;(<b>MRNA</b>)&nbsp;shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&amp;P 500 benchmark next week.</p>\n<p>Moderna will replaceAlexion Pharmaceuticals&nbsp;(<b>ALXN</b>) &nbsp;in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca&nbsp;(<b>AZN</b>)&nbsp;in December of last year.</p>\n<p>Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p>\n<p>Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p>\n<p>Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p>\n<p>\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p>\n<p>Last month, the groupformally asked the U.S. Food &amp; Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p>\n<p>Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p>\n<p>The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","AZN":"阿斯利康","ALXN":"亚力兄制药"},"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168174427","content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179672346,"gmtCreate":1626526581985,"gmtModify":1633926048848,"author":{"id":"3577103672190304","authorId":"3577103672190304","authorIdStr":"3577103672190304","name":"ziqii","avatar":"https://static.tigerbbs.com/292e38661a1a4712ada006c4ee6b3400","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577103672190304"},"htmlText":"i took moderna vaccine!","listText":"i took moderna vaccine!","text":"i took moderna vaccine!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/179672346","repostId":1168174427,"repostType":4,"repost":{"id":"1168174427","pubTimestamp":1626445586,"share":"https://www.laohu8.com/m/news/1168174427?lang=&edition=full","pubTime":"2021-07-16 22:26","market":"us","language":"en","title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500","url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","media":"Thestreet","summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","content":"<p>Moderna Inc.&nbsp;(<b>MRNA</b>)&nbsp;shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&amp;P 500 benchmark next week.</p>\n<p>Moderna will replaceAlexion Pharmaceuticals&nbsp;(<b>ALXN</b>) &nbsp;in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca&nbsp;(<b>AZN</b>)&nbsp;in December of last year.</p>\n<p>Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p>\n<p>Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p>\n<p>Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p>\n<p>\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p>\n<p>Last month, the groupformally asked the U.S. Food &amp; Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p>\n<p>Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p>\n<p>The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","AZN":"阿斯利康","ALXN":"亚力兄制药"},"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168174427","content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5262357,"gmtCreate":1626697235276,"gmtModify":1635226050555,"authorId":3577103672190304,"author":{"id":3577103672190304,"authorId":3577103672190304,"name":"ziqii","avatar":"https://static.tigerbbs.com/292e38661a1a4712ada006c4ee6b3400","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179672346,"type":1,"supId":0,"prevId":0,"content":"anybody else?","text":"anybody else?","html":"anybody else?"},{"id":5274191,"gmtCreate":1626792718511,"gmtModify":1635225196085,"authorId":3577103672190304,"author":{"id":3577103672190304,"authorId":3577103672190304,"name":"ziqii","avatar":"https://static.tigerbbs.com/292e38661a1a4712ada006c4ee6b3400","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179672346,"type":1,"supId":0,"prevId":0,"content":"no one?","text":"no one?","html":"no one?"},{"id":5283512,"gmtCreate":1626874806377,"gmtModify":1635224499559,"authorId":3571753799303202,"author":{"id":3571753799303202,"authorId":3571753799303202,"name":"ianjie","avatar":"https://static.tigerbbs.com/344b23af72e7e9f903a2a22b6a0fa2d9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179672346,"type":1,"supId":0,"prevId":0,"content":"me too!","text":"me too!","html":"me too!"},{"id":5285858,"gmtCreate":1626886559522,"gmtModify":1635224370277,"authorId":3577103672190304,"author":{"id":3577103672190304,"authorId":3577103672190304,"name":"ziqii","avatar":"https://static.tigerbbs.com/292e38661a1a4712ada006c4ee6b3400","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179672346,"type":1,"supId":5283512,"prevId":0,"content":"cool","text":"cool","html":"cool"},{"id":5315215,"gmtCreate":1627099824659,"gmtModify":1635222483117,"authorId":3577103672190304,"author":{"id":3577103672190304,"authorId":3577103672190304,"name":"ziqii","avatar":"https://static.tigerbbs.com/292e38661a1a4712ada006c4ee6b3400","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3577103672190304,"repliedAuthor":{"id":3577103672190304,"authorId":3577103672190304,"name":"ziqii","avatar":"https://static.tigerbbs.com/292e38661a1a4712ada006c4ee6b3400","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":179672346,"type":1,"supId":5283512,"prevId":5285858,"content":"cool cool","text":"cool cool","html":"cool cool"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":226,"commentSize":63,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168174427"}